{"pmid":32398294,"title":"Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?","text":["Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?","Eur Respir J","Criel, Maarten","Falter, Maarten","Jaeken, Jasmien","Van Kerrebroeck, Margaretha","Lefere, Isabelle","Meylaerts, Liesbeth","Mesotten, Dieter","Vander Laenen, Margot","Fivez, Tom","Thomeer, Michiel","David, Ruttens","32398294"],"journal":"Eur Respir J","authors":["Criel, Maarten","Falter, Maarten","Jaeken, Jasmien","Van Kerrebroeck, Margaretha","Lefere, Isabelle","Meylaerts, Liesbeth","Mesotten, Dieter","Vander Laenen, Margot","Fivez, Tom","Thomeer, Michiel","David, Ruttens"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32398294","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1183/13993003.01201-2020","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666714494868389889,"score":9.490897,"similar":[{"pmid":32294289,"title":"Venous thromboembolism in COVID-19 patients.","text":["Venous thromboembolism in COVID-19 patients.","We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days.","J Thromb Haemost","Porfidia, Angelo","Pola, Roberto","32294289"],"abstract":["We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days."],"journal":"J Thromb Haemost","authors":["Porfidia, Angelo","Pola, Roberto"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294289","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14842","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Enoxaparin","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666138494470193152,"score":52.254837},{"pmid":32369666,"title":"Incidence of venous thromboembolism in hospitalized patients with COVID-19.","text":["Incidence of venous thromboembolism in hospitalized patients with COVID-19.","Coronavirus disease 2019 (COVID-19) can lead to systemic coagulation activation and thrombotic complications. We investigated the incidence of objectively confirmed venous thromboembolism (VTE) in 198 hospitalized patients with COVID-19 in a single-center cohort study. Seventy-five patients (38%) were admitted to the intensive care unit (ICU). At time of data collection, 16 (8%) were still hospitalized and 19% had died. During a median follow-up of 7 days (IQR, 3-13), 39 patients (20%) were diagnosed with VTE of whom 25 (13%) had symptomatic VTE, despite routine thrombosis prophylaxis. The cumulative incidences of VTE at 7, 14 and 21 days were 16% (95% CI, 10-22), 33% (95% CI, 23-43) and 42% (95% CI 30-54) respectively. For symptomatic VTE, these were 10% (95% CI, 5.8-16), 21% (95% CI, 14-30) and 25% (95% CI 16-36). VTE appeared to be associated with death (adjusted HR, 2.4; 95% CI, 1.02-5.5). The cumulative incidence of VTE was higher in the ICU (26% (95% CI, 17-37), 47% (95% CI, 34-58), and 59% (95% CI, 42-72) at 7, 14 and 21 days) than on the wards (any VTE and symptomatic VTE 5.8% (95% CI, 1.4-15), 9.2% (95% CI, 2.6-21), and 9.2% (2.6-21) at 7, 14, and 21 days). The observed risk for VTE in COVID-19 is high, particularly in ICU patients, which should lead to a high level of clinical suspicion and low threshold for diagnostic imaging for DVT or PE. Future research should focus on optimal diagnostic and prophylactic strategies to prevent VTE and potentially improve survival.","J Thromb Haemost","Middeldorp, Saskia","Coppens, Michiel","van Haaps, Thijs F","Foppen, Merijn","Vlaar, Alexander P","Muller, Marcella C A","Bouman, Catherine C S","Beenen, Ludo F M","Kootte, Ruud S","Heijmans, Jarom","Smits, Loek P","Bonta, Peter I","van Es, Nick","32369666"],"abstract":["Coronavirus disease 2019 (COVID-19) can lead to systemic coagulation activation and thrombotic complications. We investigated the incidence of objectively confirmed venous thromboembolism (VTE) in 198 hospitalized patients with COVID-19 in a single-center cohort study. Seventy-five patients (38%) were admitted to the intensive care unit (ICU). At time of data collection, 16 (8%) were still hospitalized and 19% had died. During a median follow-up of 7 days (IQR, 3-13), 39 patients (20%) were diagnosed with VTE of whom 25 (13%) had symptomatic VTE, despite routine thrombosis prophylaxis. The cumulative incidences of VTE at 7, 14 and 21 days were 16% (95% CI, 10-22), 33% (95% CI, 23-43) and 42% (95% CI 30-54) respectively. For symptomatic VTE, these were 10% (95% CI, 5.8-16), 21% (95% CI, 14-30) and 25% (95% CI 16-36). VTE appeared to be associated with death (adjusted HR, 2.4; 95% CI, 1.02-5.5). The cumulative incidence of VTE was higher in the ICU (26% (95% CI, 17-37), 47% (95% CI, 34-58), and 59% (95% CI, 42-72) at 7, 14 and 21 days) than on the wards (any VTE and symptomatic VTE 5.8% (95% CI, 1.4-15), 9.2% (95% CI, 2.6-21), and 9.2% (2.6-21) at 7, 14, and 21 days). The observed risk for VTE in COVID-19 is high, particularly in ICU patients, which should lead to a high level of clinical suspicion and low threshold for diagnostic imaging for DVT or PE. Future research should focus on optimal diagnostic and prophylactic strategies to prevent VTE and potentially improve survival."],"journal":"J Thromb Haemost","authors":["Middeldorp, Saskia","Coppens, Michiel","van Haaps, Thijs F","Foppen, Merijn","Vlaar, Alexander P","Muller, Marcella C A","Bouman, Catherine C S","Beenen, Ludo F M","Kootte, Ruud S","Heijmans, Jarom","Smits, Loek P","Bonta, Peter I","van Es, Nick"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369666","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jth.14888","locations":["optimal"],"topics":["Diagnosis"],"weight":1,"_version_":1666138496266403840,"score":49.703426},{"pmid":32474397,"title":"Venous thromboembolism and COVID-19.","text":["Venous thromboembolism and COVID-19.","Respir Med Res","Bertoletti, L","Couturaud, F","Montani, D","Parent, F","Sanchez, O","32474397"],"journal":"Respir Med Res","authors":["Bertoletti, L","Couturaud, F","Montani, D","Parent, F","Sanchez, O"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474397","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.resmer.2020.100759","keywords":["covid-19","coronavirus disease","pulmonary embolism","sars-cov-2","venous thromboembolic disease"],"topics":["Treatment"],"weight":1,"_version_":1668341932680544257,"score":49.555508},{"pmid":32425261,"pmcid":"PMC7227496","title":"Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism.","text":["Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism.","*COVID-19 pneumonia could be associated with an increased risk of venous thrombosis.*Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients.*Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low.","Thromb Res","Galeano-Valle, F","Oblitas, C M","Ferreiro-Mazon, M M","Alonso-Munoz, J","Del Toro-Cervera, J","Demelo-Rodriguez, P","32425261"],"abstract":["*COVID-19 pneumonia could be associated with an increased risk of venous thrombosis.*Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients.*Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low."],"journal":"Thromb Res","authors":["Galeano-Valle, F","Oblitas, C M","Ferreiro-Mazon, M M","Alonso-Munoz, J","Del Toro-Cervera, J","Demelo-Rodriguez, P"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425261","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.thromres.2020.05.017","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667352728760745984,"score":49.439465},{"pmid":32504449,"title":"Diagnosis of venous and arterial thromboembolic events in COVID-19 virus-infected patients.","text":["Diagnosis of venous and arterial thromboembolic events in COVID-19 virus-infected patients.","J Thromb Thrombolysis","Betoule, Anna","Martinet, Camille","Gasperini, Guillaume","Muller, Pauline","Foucher, Stephane","Benner, Patrick","Renard, Aurelien","32504449"],"journal":"J Thromb Thrombolysis","authors":["Betoule, Anna","Martinet, Camille","Gasperini, Guillaume","Muller, Pauline","Foucher, Stephane","Benner, Patrick","Renard, Aurelien"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504449","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s11239-020-02163-y","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668892488325136384,"score":49.439465}]}